E48: ADACTA - Tocilizumab or Adalimumab in MTX Intolerant Patients with RA
This week I revisit an old paper - the 2013 ADACTA trial that assessed tocilizumab and adalimumab for patients who cannot take or were intolerant of MTX.
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"The Evidence Based Rheumatology Podcast","authorlink":""},"src":"https:\/\/mcdn.podbean.com\/mf\/web\/7379at\/e48.mp3","thumb":{"src":"https:\/\/images.lystnfm.com\/tr:n-app_thumbnail_medium\/podcastsnw-202211\/633496-0633-b9b6-7f2bb9_800.jpg"},"title":"E48: ADACTA - Tocilizumab or Adalimumab in MTX Intolerant Patients with RA","link":"javascript:;","id":"item-262697"}]
